AstraZeneca Opposes High Court Answering If ANDA Subjects Filers To Personal Jurisdiction

(December 2, 2016, 1:43 PM EST) -- WASHINGTON, D.C. — AstraZeneca AB argues in a Nov. 21 opposition brief that the U.S. Supreme Court should decline to answer whether the filing of an abbreviated new drug application (ANDA)...
To view the full article, register now.